Drug Design Flashcards

1
Q

gene therapy work by:

A

having a vector carrying a new gene into the cell. The gene will replace something that is missing or damaged.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Example disease tx that gene therapy is use:

A

Cystic fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Cystic fibrosis is

A

a genetic disorder that lead to mutant receptors production. (inability to transport chloride from the airway lumen into the airway epithelial cells –>bc of the mutant receptor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Gene therapy working for cystic fibrosis by

A

deliverying new receptor gene via nasal spray to be taken up by the airway epithelial cells to make functionnal chloride channels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Microarray technology is use to

A

determine which genes of the genome are expressed in diff tissues under diff. circumstances.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Bioinformatics is

A

use to get info we need by looking at thousands of situations/samples.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Steps DRUG DISCOVERY:

A
  1. Compare tumour with normal cells. (gene they express and protein)
  2. Info obtain provide insights about novels molecular targets.
  3. Target validation (to know if it is useful at the end)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Stage in drug design:

A
  1. Drug discovery
  2. preclinical
  3. clinical trials
  4. FDA review
  5. Clinic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

In preclinical studies we use

A

combinatory chemistry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Lead optimization is

A

the improvement of the lead compound base on animals and cells studies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

High throughput screening is?

done by?

A

put enourmous amount of compounds through the screening test. (mass screening)
Done by robots.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

2 types of assays

A

Cell-free assays (ligands-receptor interactions.)

Cell-based assays (receptor gene expression or sec messenger.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

High throughput screening cannot evaluate:

A
Bioavailability
Pharmacokinetics
Toxicity
Mutagenicity
Specificity*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Subcellular fraction is use for?

A

testing drugs candidates (spectrometry..)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Computational chemistry is

A

branch of chemistry that uses computer simulation to assist in solving chemical problems.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Drug treating AIDS (HIV virus) is

A

HIV protease inhibitor (block the enzyme in HIV virus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Ibrutinib is

A

cancerous B cells drug–> blocking enzyme overexpressed in B cells malignancies

18
Q

enzyme PCSK9 is

A

enzyme that normally delays the removal of LDL-C via LDL-R into the liver.

19
Q

Action of enzyme PCSK9: (in the hepatocyte)

A

LDL particle taken in by binding to the LDL receptor–> LDL particle is digested(destruction of lysosome in the liver) and broken down inside the cell.

20
Q

PCSK9 inhibitor effect:

A

LDL receptors will not be degraded, it will be recycled and re-expressed back onto the surface. (more receptors for more LDL-C for degradation)

21
Q

breast cancer specific targets:

A

Blocking HER2 protein.

22
Q

Infliximab is what type of MAb:

A

chimeric IgG1 MAb drugs binding to TNFa (tumor necrosis factor)

23
Q

Colorectal carcinoma receptors:

A

EGFR (epidermal growth factor receptor)

VEGFR1 (vascular endothelial growth factor receptor 1)

24
Q

During pre-clinical evaluation, we can do:

A

initial pharmacokinetics studies (on animal)

25
Placebo responses can be monitored in the brain but also:
- descending pathway in the spinal cord - hormone and cytokine release - changes in cardiovasc and immun syst. - Psychological responses (eg.mood) - Autonomic changes in the GI tract
26
Who are the most vulnerable to placebo responses?
Children
27
Priority of toxicogenomics
look to adverse reactions | to detect the small nb of people with negative effects
28
Drugs failling the drug development process is due to
1. lack of efficacy | 2. lack of safety
29
Phase 1
safety phamacokinetics dose range Healthy volunteers
30
Ibrutinib (Imbruvica)
block enzyme overexpressed in B cell malignancies (block the kinase) Tx Chronic lymphocytic leukemia (CLL) Bind with cystein-481 in the enzyme ( Bruton's tyrosine kinase, BTK)
31
Phase 2
Effectiveness expand pharmacokinetics studies Prediction of toxicology 100-300 volunteers with medical conditions targeting
32
Phase 3
Verify effectiveness Long-term effect studies 1000-3000 volunteers with the med conditions targeting. RCTs, double-blind, randomized, parallel or crossover design
33
Elements that can biais long-term studies of drugs and need to be MONITORED:
- Lifestyles (compliance to the tx, alimentation...) - Different stage of the illness (ulcers healing vs ulcers relapse overtime) - Side effects can biais the patient reaction (lorazepam sedative effect biais patient say that it help.. but not really. Only bc of the side effect) - Beliefs and psychosocial context
34
Phase 4
Effectiveness in the general population Safety observed Occurs once drugs is on market
35
PCSK9 is
bind to LDL receptor and go to the endosome and is digested in the lysosome.
36
PCSK9 inhibitor
Decrease heart disease (cholesterol level)
37
Neprilysin
Break natriuretic and other vasoactive peptides into inactive metabolites.
38
Neprilysin inhibitor
Naturally decrease BP, promote sodium excretion. | to Tx heart failure.
39
Sovaldi ( Sofosbuvir)
target the replication of virus RNA replication of Hepatitis C
40
Mutagenicity testing can be done during the pre-clinical evaluation by:
AMES test, which use bacteria, or mutagen test using yeasts